JP2017537629A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017537629A5 JP2017537629A5 JP2017529741A JP2017529741A JP2017537629A5 JP 2017537629 A5 JP2017537629 A5 JP 2017537629A5 JP 2017529741 A JP2017529741 A JP 2017529741A JP 2017529741 A JP2017529741 A JP 2017529741A JP 2017537629 A5 JP2017537629 A5 JP 2017537629A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- set forth
- chain variable
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001413 amino acids Chemical class 0.000 claims description 1158
- 230000004048 modification Effects 0.000 claims description 404
- 238000012986 modification Methods 0.000 claims description 404
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 220
- 239000000427 antigen Substances 0.000 claims description 172
- 102000036639 antigens Human genes 0.000 claims description 172
- 108091007433 antigens Proteins 0.000 claims description 172
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 80
- 229920001184 polypeptide Polymers 0.000 claims description 76
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 76
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 56
- 150000007523 nucleic acids Chemical class 0.000 claims description 48
- 108020004707 nucleic acids Proteins 0.000 claims description 46
- 102000039446 nucleic acids Human genes 0.000 claims description 46
- 210000004027 cell Anatomy 0.000 claims description 44
- 206010028980 Neoplasm Diseases 0.000 claims description 34
- 230000009826 neoplastic cell growth Effects 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 21
- 208000034578 Multiple myelomas Diseases 0.000 claims description 20
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 20
- 230000011664 signaling Effects 0.000 claims description 16
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 14
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 14
- 230000000139 costimulatory effect Effects 0.000 claims description 14
- 102100021197 G-protein coupled receptor family C group 5 member D Human genes 0.000 claims description 12
- 230000003834 intracellular effect Effects 0.000 claims description 12
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 claims description 10
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 claims description 10
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 10
- 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 claims description 9
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims description 9
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 8
- 101001040713 Homo sapiens G-protein coupled receptor family C group 5 member D Proteins 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 102000004127 Cytokines Human genes 0.000 claims description 6
- 108090000695 Cytokines Proteins 0.000 claims description 6
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 6
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 6
- 239000003446 ligand Substances 0.000 claims description 6
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims description 4
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 4
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims description 4
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 4
- 101710174800 G-protein coupled receptor family C group 5 member D Proteins 0.000 claims description 4
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims description 4
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 4
- 230000028993 immune response Effects 0.000 claims description 4
- 210000001778 pluripotent stem cell Anatomy 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 230000004083 survival effect Effects 0.000 claims description 3
- 210000004881 tumor cell Anatomy 0.000 claims description 3
- 108010082808 4-1BB Ligand Proteins 0.000 claims description 2
- 102100036008 CD48 antigen Human genes 0.000 claims description 2
- 102100025221 CD70 antigen Human genes 0.000 claims description 2
- -1 CD86 Proteins 0.000 claims description 2
- 101000716130 Homo sapiens CD48 antigen Proteins 0.000 claims description 2
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 claims description 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 2
- 101000648507 Homo sapiens Tumor necrosis factor receptor superfamily member 14 Proteins 0.000 claims description 2
- 108090000177 Interleukin-11 Proteins 0.000 claims description 2
- 108010065805 Interleukin-12 Proteins 0.000 claims description 2
- 108090000172 Interleukin-15 Proteins 0.000 claims description 2
- 108050003558 Interleukin-17 Proteins 0.000 claims description 2
- 108010002350 Interleukin-2 Proteins 0.000 claims description 2
- 108010002386 Interleukin-3 Proteins 0.000 claims description 2
- 108090001005 Interleukin-6 Proteins 0.000 claims description 2
- 108010002586 Interleukin-7 Proteins 0.000 claims description 2
- 102000017578 LAG3 Human genes 0.000 claims description 2
- 101150030213 Lag3 gene Proteins 0.000 claims description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 2
- 108010042215 OX40 Ligand Proteins 0.000 claims description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 2
- 101100225046 Schizosaccharomyces pombe (strain 972 / ATCC 24843) ecl2 gene Proteins 0.000 claims description 2
- 101100225047 Schizosaccharomyces pombe (strain 972 / ATCC 24843) ecl3 gene Proteins 0.000 claims description 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims description 2
- 102100026890 Tumor necrosis factor ligand superfamily member 4 Human genes 0.000 claims description 2
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 claims description 2
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims description 2
- 101150058725 ecl1 gene Proteins 0.000 claims description 2
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims description 2
- 108020001507 fusion proteins Proteins 0.000 claims description 2
- 102000037865 fusion proteins Human genes 0.000 claims description 2
- 108010074108 interleukin-21 Proteins 0.000 claims description 2
- 210000004698 lymphocyte Anatomy 0.000 claims description 2
- 210000003738 lymphoid progenitor cell Anatomy 0.000 claims description 2
- 210000004897 n-terminal region Anatomy 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 210000003289 regulatory T cell Anatomy 0.000 claims description 2
- 210000000130 stem cell Anatomy 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 14
- 230000004043 responsiveness Effects 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462088286P | 2014-12-05 | 2014-12-05 | |
| US62/088,286 | 2014-12-05 | ||
| PCT/US2015/064102 WO2016090312A1 (en) | 2014-12-05 | 2015-12-04 | Chimeric antigen receptors targeting g-protein coupled receptor and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020198690A Division JP2021040652A (ja) | 2014-12-05 | 2020-11-30 | Ｇタンパク質共役受容体を標的化するキメラ抗原受容体およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017537629A JP2017537629A (ja) | 2017-12-21 |
| JP2017537629A5 true JP2017537629A5 (enExample) | 2019-01-17 |
| JP6919091B2 JP6919091B2 (ja) | 2021-08-18 |
Family
ID=56092565
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017529741A Active JP6919091B2 (ja) | 2014-12-05 | 2015-12-04 | Ｇタンパク質共役受容体を標的化するキメラ抗原受容体およびその使用 |
| JP2020198690A Withdrawn JP2021040652A (ja) | 2014-12-05 | 2020-11-30 | Ｇタンパク質共役受容体を標的化するキメラ抗原受容体およびその使用 |
| JP2023079310A Withdrawn JP2023091037A (ja) | 2014-12-05 | 2023-05-12 | Ｇタンパク質共役受容体を標的化するキメラ抗原受容体およびその使用 |
| JP2025156538A Pending JP2025181929A (ja) | 2014-12-05 | 2025-09-19 | Ｇタンパク質共役受容体を標的化するキメラ抗原受容体およびその使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020198690A Withdrawn JP2021040652A (ja) | 2014-12-05 | 2020-11-30 | Ｇタンパク質共役受容体を標的化するキメラ抗原受容体およびその使用 |
| JP2023079310A Withdrawn JP2023091037A (ja) | 2014-12-05 | 2023-05-12 | Ｇタンパク質共役受容体を標的化するキメラ抗原受容体およびその使用 |
| JP2025156538A Pending JP2025181929A (ja) | 2014-12-05 | 2025-09-19 | Ｇタンパク質共役受容体を標的化するキメラ抗原受容体およびその使用 |
Country Status (26)
| Country | Link |
|---|---|
| US (5) | US10633426B2 (enExample) |
| EP (2) | EP3227339B1 (enExample) |
| JP (4) | JP6919091B2 (enExample) |
| KR (1) | KR102612367B1 (enExample) |
| CN (4) | CN107428829B (enExample) |
| AU (2) | AU2015357518B2 (enExample) |
| CA (1) | CA2969864A1 (enExample) |
| CY (1) | CY1125008T1 (enExample) |
| DK (1) | DK3227339T3 (enExample) |
| ES (1) | ES2899779T3 (enExample) |
| HR (1) | HRP20211978T1 (enExample) |
| HU (1) | HUE057777T2 (enExample) |
| IL (2) | IL252621B2 (enExample) |
| LT (1) | LT3227339T (enExample) |
| MX (2) | MX385156B (enExample) |
| MY (1) | MY192065A (enExample) |
| PH (1) | PH12017501044A1 (enExample) |
| PL (1) | PL3227339T3 (enExample) |
| PT (1) | PT3227339T (enExample) |
| RS (1) | RS62870B1 (enExample) |
| RU (1) | RU2762359C2 (enExample) |
| SA (1) | SA517381665B1 (enExample) |
| SG (2) | SG11201704547RA (enExample) |
| SI (1) | SI3227339T1 (enExample) |
| SM (1) | SMT202200040T1 (enExample) |
| WO (1) | WO2016090312A1 (enExample) |
Families Citing this family (96)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230159637A (ko) * | 2014-12-05 | 2023-11-21 | 메모리얼 슬로안 케터링 캔서 센터 | G-단백질 커플화 수용체를 표적화하는 항체 및 이의 사용 방법 |
| PT3227339T (pt) | 2014-12-05 | 2022-01-14 | Eureka Therapeutics Inc | Recetores de antigénio quiméricos que têm como alvo o recetor 4 acoplado a proteína g e utilizações dos mesmos |
| MX2017014822A (es) | 2015-05-18 | 2018-04-30 | Tcr2 Therapeutics Inc | Composiciones y métodos para la reprogramación del tcr con proteínas de fusión. |
| US20190233533A1 (en) | 2016-06-28 | 2019-08-01 | Umc Utrecht Holding B.V. | Treatment Of IgE-Mediated Diseases With Antibodies That Specifically Bind CD38 |
| CA3032498A1 (en) | 2016-08-02 | 2018-02-08 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| CA3032806C (en) | 2016-08-05 | 2021-04-27 | Y-Biologics Inc. | Antibody to programmed death-ligand 1 (pd-l1) and use thereof |
| MX2019003899A (es) | 2016-10-07 | 2019-08-14 | Tcr2 Therapeutics Inc | Composiciones y metodos para reprogramacion de receptores de linfocitos t mediante el uso de proteinas de fusion. |
| EP3544996A2 (en) | 2016-11-22 | 2019-10-02 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| WO2018102795A2 (en) | 2016-12-02 | 2018-06-07 | University Of Southern California | Synthetic immune receptors and methods of use thereof |
| WO2018127918A1 (en) | 2017-01-05 | 2018-07-12 | Kahr Medical Ltd. | A sirp alpha-cd70 fusion protein and methods of use thereof |
| HRP20230937T1 (hr) | 2017-01-05 | 2023-11-24 | Kahr Medical Ltd. | Pd1-41bbl fuzijski protein i metode korištenja istog |
| WO2018127916A1 (en) | 2017-01-05 | 2018-07-12 | Kahr Medical Ltd. | A pd1-cd70 fusion protein and methods of use thereof |
| PT3565828T (pt) | 2017-01-05 | 2022-02-08 | Kahr Medical Ltd | Proteína de fusão sirp1 alfa-41bbl e seus métodos de utilização |
| WO2018147245A1 (ja) * | 2017-02-07 | 2018-08-16 | 第一三共株式会社 | 抗ｇｐｒｃ５ｄ抗体及び該抗体を含む分子 |
| CN110741016A (zh) | 2017-04-26 | 2020-01-31 | 优瑞科生物技术公司 | 嵌合抗体/t-细胞受体构筑体及其用途 |
| KR20250096881A (ko) | 2017-08-09 | 2025-06-27 | 주노 쎄러퓨티크스 인코퍼레이티드 | 유전자 조작된 세포를 제조하기 위한 방법 및 조성물 |
| WO2019032927A1 (en) | 2017-08-09 | 2019-02-14 | Juno Therapeutics, Inc. | METHODS FOR PRODUCING GENETICALLY MODIFIED CELL COMPOSITIONS AND COMPOSITIONS THEREOF |
| US20200292526A1 (en) | 2017-09-07 | 2020-09-17 | Juno Therapeutics, Inc. | Methods of identifying cellular attributes related to outcomes associated with cell therapy |
| WO2019089855A1 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Process for generating therapeutic compositions of engineered cells |
| US11564946B2 (en) | 2017-11-01 | 2023-01-31 | Juno Therapeutics, Inc. | Methods associated with tumor burden for assessing response to a cell therapy |
| WO2019089858A2 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Methods of assessing or monitoring a response to a cell therapy |
| KR20200074997A (ko) | 2017-11-01 | 2020-06-25 | 주노 쎄러퓨티크스 인코퍼레이티드 | B-세포 성숙 항원에 특이적인 항체 및 키메릭 항원 수용체 |
| KR102845789B1 (ko) | 2017-11-01 | 2025-08-14 | 주노 쎄러퓨티크스 인코퍼레이티드 | B 세포 성숙 항원에 특이적인 키메라 항원 수용체 및 암호화 폴리뉴클레오타이드 |
| SG11202003657VA (en) | 2017-11-01 | 2020-05-28 | Juno Therapeutics Inc | Process for producing a t cell composition |
| WO2019099483A1 (en) * | 2017-11-14 | 2019-05-23 | Memorial Sloan-Kettering Cancer Center | Il-36 secreting immunoresponsive cells and uses thereof |
| CN111989106A (zh) | 2017-12-01 | 2020-11-24 | 朱诺治疗学股份有限公司 | 基因工程化细胞的给药和调节方法 |
| SG11202005217VA (en) | 2017-12-08 | 2020-07-29 | Juno Therapeutics Inc | Phenotypic markers for cell therapy and related methods |
| WO2019113557A1 (en) | 2017-12-08 | 2019-06-13 | Juno Therapeutics, Inc. | Process for producing a composition of engineered t cells |
| AU2018379091A1 (en) | 2017-12-08 | 2020-06-25 | Juno Therapeutics, Inc. | Serum-free media formulation for culturing cells and methods of use thereof |
| CN112888709B (zh) * | 2018-03-30 | 2024-10-29 | 优瑞科生物技术公司 | 标靶cd22的构建体和其用途 |
| CA3100157A1 (en) * | 2018-05-16 | 2019-11-21 | Janssen Biotech, Inc. | Methods of treating cancers and enhancing efficacy of t cell redirecting therapeutics |
| KR20210044220A (ko) | 2018-07-11 | 2021-04-22 | 카 메디컬 리미티드 | SIRPalpha-4-1BBL 변이체 융합 단백질 및 이의 사용 방법 |
| SG11202013170RA (en) | 2018-07-11 | 2021-01-28 | Kahr Medical Ltd | Pd1-4-1bbl variant fusion protein and methods of use thereof |
| MX2021001519A (es) | 2018-08-09 | 2021-05-27 | Juno Therapeutics Inc | Metodos para valorar acidos nucleicos integrados. |
| CA3108657A1 (en) | 2018-08-09 | 2020-02-13 | Juno Therapeutics, Inc. | Processes for generating engineered cells and compositions thereof |
| JP7672340B2 (ja) * | 2018-10-19 | 2025-05-07 | メモリアル スローン ケタリング キャンサー センター | シアリルルイスａを標的とするキメラ抗原受容体およびその使用 |
| US12522660B2 (en) | 2018-10-31 | 2026-01-13 | C3S2 Gmbh | Methods for selection and stimulation of cells and apparatus for same |
| MX2021005024A (es) | 2018-11-01 | 2021-07-21 | Juno Therapeutics Inc | Metodos de tratamiento que utilizan receptores de antigenos quimericos especificos para antigeno de maduracion de celulas b. |
| CA3116413A1 (en) * | 2018-11-01 | 2020-05-07 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for g protein-coupled receptor class c group 5 member d (gprc5d) |
| FI3886875T3 (fi) | 2018-11-30 | 2024-07-23 | Juno Therapeutics Inc | Adoptiivista soluterapiaa käyttäviä hoitomenetelmiä |
| PE20211977A1 (es) * | 2019-01-18 | 2021-10-05 | Janssen Biotech Inc | Receptores de antigenos quimericos de gprc5d y celulas que los expresan |
| AU2020265749A1 (en) | 2019-05-01 | 2022-01-06 | Juno Therapeutics, Inc. | Cells expressing a chimeric receptor from a modified CD247 locus, related polynucleotides and methods |
| SG11202111360YA (en) | 2019-05-01 | 2021-11-29 | Juno Therapeutics Inc | Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods |
| MA56206A (fr) | 2019-06-12 | 2022-04-20 | Juno Therapeutics Inc | Combinaison thérapeutique d'une thérapie cytotoxique à médiation cellulaire et d'un inhibiteur d'une protéine de la famille bcl2 pro-survie |
| US20220298222A1 (en) | 2019-08-22 | 2022-09-22 | Juno Therapeutics, Inc. | Combination therapy of a t cell therapy and an enhancer of zeste homolog 2 (ezh2) inhibitor and related methods |
| EP4021582A1 (en) | 2019-08-30 | 2022-07-06 | Allogene Therapeutics, Inc. | Chimeric cytokine receptors comprising tgf beta binding domains |
| IL292319B2 (en) | 2019-10-30 | 2026-01-01 | C3S2 Gmbh | Cell selection and/or stimulation devices and methods of use |
| CN115335399A (zh) | 2019-12-06 | 2022-11-11 | 朱诺治疗学股份有限公司 | 针对gprc5d靶结合结构域的抗独特型抗体以及相关组合物和方法 |
| US10980836B1 (en) | 2019-12-11 | 2021-04-20 | Myeloid Therapeutics, Inc. | Therapeutic cell compositions and methods of manufacturing and use thereof |
| US20230090117A1 (en) | 2020-01-28 | 2023-03-23 | Juno Therapeutics, Inc. | Methods for t cell transduction |
| EP4132579A4 (en) | 2020-04-10 | 2024-05-22 | Invivyd, Inc. | CORONAVIRUS S-PROTEIN SPECIFIC COMPOUNDS AND USES THEREOF |
| EP4150640A1 (en) | 2020-05-13 | 2023-03-22 | Juno Therapeutics, Inc. | Methods of identifying features associated with clinical response and uses thereof |
| EP4171616A1 (en) | 2020-06-26 | 2023-05-03 | Juno Therapeutics GmbH | Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods |
| JP2023549780A (ja) | 2020-11-04 | 2023-11-29 | ジュノー セラピューティクス インコーポレイテッド | 改変されたインバリアントｃｄ３免疫グロブリンスーパーファミリー鎖遺伝子座からキメラ受容体を発現する細胞ならびに関連するポリヌクレオチドおよび方法 |
| CN116635064A (zh) | 2020-12-18 | 2023-08-22 | 世纪治疗股份有限公司 | 具有适应性受体特异性的嵌合抗原受体系统 |
| WO2022148370A1 (en) * | 2021-01-05 | 2022-07-14 | Lanova Medicines Development Co., Ltd. | Anti-gprc5d monoclonal antibodies and uses thereof |
| US20240108654A1 (en) | 2021-03-03 | 2024-04-04 | Juno Therapeutics, Inc. | Combination of a t cell therapy and a dgk inhibitor |
| CA3212398A1 (en) | 2021-03-17 | 2022-09-22 | Daniel Getts | Engineered chimeric fusion protein compositions and methods of use thereof |
| AU2022244229A1 (en) | 2021-03-22 | 2023-09-14 | Juno Therapeutics, Inc. | Method to assess potency of viral vector particles |
| CA3210581A1 (en) | 2021-03-22 | 2022-09-29 | Neil HAIG | Methods of determining potency of a therapeutic cell composition |
| MX2023011862A (es) * | 2021-04-07 | 2024-01-08 | Lg Chemical Ltd | Polipeptido de union a gucy2c y usos del mismo. |
| KR20240018454A (ko) | 2021-05-06 | 2024-02-13 | 주노 테라퓨틱스 게엠베하 | T 세포의 자극 및 형질도입 방법 |
| CN115386010B (zh) * | 2021-05-23 | 2026-02-06 | 上海邦耀生物科技有限公司 | 靶向gprc5d的嵌合抗原受体及其用途 |
| WO2023030272A1 (zh) | 2021-08-30 | 2023-03-09 | 原启生物科技(上海)有限责任公司 | 抗gprc5d抗原结合蛋白及其用途 |
| JP2024540304A (ja) | 2021-11-03 | 2024-10-31 | ヤンセン バイオテツク，インコーポレーテツド | 抗ｃｄ３８抗体による治療におけるコルチコステロイドの減少 |
| US20250057950A1 (en) | 2022-01-14 | 2025-02-20 | Oricell Therapeutics Co., Ltd. | Chimeric antigen receptor targeting gprc5d and application thereof |
| CN119013393A (zh) | 2022-01-28 | 2024-11-22 | 朱诺治疗学股份有限公司 | 制造细胞组合物的方法 |
| WO2023143537A1 (zh) | 2022-01-29 | 2023-08-03 | 恺兴生命科技(上海)有限公司 | Gprc5d抗体及其应用 |
| US20250297282A1 (en) | 2022-05-05 | 2025-09-25 | Juno Therapeutics Gmbh | Viral-binding protein and related reagents, articles, and methods of use |
| US20250302954A1 (en) | 2022-05-11 | 2025-10-02 | Celgene Corporation | Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy |
| EP4525899A1 (en) | 2022-05-17 | 2025-03-26 | Umoja Biopharma, Inc. | Manufacturing viral particles |
| WO2023230581A1 (en) | 2022-05-25 | 2023-11-30 | Celgene Corporation | Methods of manufacturing t cell therapies |
| CA3259061A1 (en) | 2022-06-10 | 2023-12-14 | Umoja Biopharma, Inc. | MODIFIED STEM CELLS AND THEIR USES |
| WO2023250122A1 (en) * | 2022-06-24 | 2023-12-28 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Molecules that bind to enpp1 polypeptides |
| CA3259982A1 (en) | 2022-06-30 | 2024-01-04 | Indapta Therapeutics, Inc. | COMBINATION OF MODIFIED NATURAL KILLER (NK) CELLS AND ANTIBODY THERAPY AND ASSOCIATED METHODS |
| KR20250047766A (ko) | 2022-08-05 | 2025-04-04 | 주노 쎄러퓨티크스 인코퍼레이티드 | Gprc5d 및 bcma에 특이적인 키메라 항원 수용체 |
| CN116003598B (zh) | 2022-08-30 | 2024-04-26 | 苏州缔码生物科技有限公司 | 靶向人gprc5d的重组人源化单克隆抗体及其应用 |
| EP4583876A1 (en) | 2022-09-08 | 2025-07-16 | Juno Therapeutics, Inc. | Combination of a t cell therapy and continuous or intermittent dgk inhibitor dosing |
| TW202434735A (zh) | 2022-11-04 | 2024-09-01 | 美商烏莫賈生物製藥股份有限公司 | 展示黏著分子融合的顆粒 |
| EP4615960A1 (en) | 2022-11-09 | 2025-09-17 | C3S2 GmbH | Methods for manufacturing engineered immune cells |
| WO2024102954A1 (en) | 2022-11-10 | 2024-05-16 | Massachusetts Institute Of Technology | Activation induced clipping system (aics) |
| CN121002052A (zh) | 2023-02-03 | 2025-11-21 | C3S2 有限公司 | 用于非病毒生产工程化免疫细胞的方法 |
| CN121311765A (zh) | 2023-04-18 | 2026-01-09 | 朱诺治疗学股份有限公司 | 评估治疗性细胞组合物的效力的细胞毒性测定 |
| KR20260026101A (ko) | 2023-05-23 | 2026-02-25 | 주노 쎄러퓨티크스 인코퍼레이티드 | T 세포의 활성화 마커 및 t 세포 활성화를 평가하는 방법 |
| EP4520346A1 (en) * | 2023-09-06 | 2025-03-12 | Gyncentrum Sp. z o.o. | Cells, methods and systems for use in the treatment of a cancer with dual-car-t |
| WO2025059362A1 (en) | 2023-09-13 | 2025-03-20 | Juno Therapeutics, Inc. | Combination therapies with a cell therapy expressing a gprc5d-targeting car and related methods and uses |
| WO2025076472A1 (en) | 2023-10-06 | 2025-04-10 | Juno Therapeutics, Inc. | Combination therapies with a cell therapy expressing a gprc5d-targeting car and related methods and uses |
| CN117229407B (zh) * | 2023-11-14 | 2024-02-20 | 成都优赛诺生物科技有限公司 | 一种靶向gprc5d的单域抗体、嵌合抗原受体及其应用 |
| WO2025129084A1 (en) | 2023-12-13 | 2025-06-19 | Umoja Biopharma, Inc. | Engineered induced stem cell derived myeloid cells and methods of differentiating and using same |
| WO2025147545A1 (en) | 2024-01-03 | 2025-07-10 | Juno Therapeutics, Inc. | Lipid nanoparticles for delivery of nucleic acids and related methods and uses |
| WO2025231174A1 (en) | 2024-04-30 | 2025-11-06 | Umoja Biopharma, Inc. | Manufacturing viral particles |
| WO2025231408A2 (en) | 2024-05-03 | 2025-11-06 | Janssen Biotech, Inc. | Methods for treating multiple myeloma with car-t cells and bispecific antibodies |
| WO2025231372A2 (en) | 2024-05-03 | 2025-11-06 | Janssen Biotech, Inc. | Methods for treating multiple myeloma with car-t cells and bispecific antibodies |
| WO2025235604A1 (en) | 2024-05-08 | 2025-11-13 | Umoja Biopharma, Inc. | Fusion protein for use as immune cell engager |
| WO2026020055A2 (en) | 2024-07-18 | 2026-01-22 | Juno Therapeutics, Inc. | Methods for assessing exosomes in a cell composition and related uses |
| WO2026025092A1 (en) | 2024-07-26 | 2026-01-29 | Juno Therapeutics, Inc. | Synthetic promoters for t cell expression |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| JPS6412935A (en) | 1987-07-02 | 1989-01-17 | Mitsubishi Electric Corp | Constant-speed travel device for vehicle |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| US6436703B1 (en) | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
| DE60143798D1 (de) | 2000-06-16 | 2011-02-17 | Cambridge Antibody Tech | Immunspezifisch bindende antikörper gegen blys |
| WO2003016553A2 (en) | 2001-08-20 | 2003-02-27 | Genentech, Inc. | Gpcr-like retinoic acid-induced gene 1 protein and nucleic acid |
| EP1468694A1 (en) * | 2001-12-27 | 2004-10-20 | Sumitomo Pharmaceuticals Company, Limited | Remedies for anorexia or lifestyle-related diseases and method of screening the same |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| US20040110139A1 (en) * | 2002-12-10 | 2004-06-10 | Isis Pharmaceuticals Inc. | Modulation of G protein-coupled receptor 3 expression |
| WO2004058171A2 (en) | 2002-12-20 | 2004-07-15 | Protein Design Labs, Inc. | Antibodies against gpr64 and uses thereof |
| WO2004072117A2 (en) | 2003-02-13 | 2004-08-26 | Pharmacia Corporation | Antibodies to c-met for the treatment of cancers |
| WO2005019258A2 (en) | 2003-08-11 | 2005-03-03 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| KR101333449B1 (ko) * | 2003-12-10 | 2013-11-26 | 메다렉스, 엘.엘.시. | Ｉｐ―１０ 항체 및 그의 용도 |
| US20050266008A1 (en) * | 2004-03-29 | 2005-12-01 | Medarex, Inc. | Human anti-IRTA-5 antibodies |
| EP2064244B1 (en) | 2006-08-03 | 2019-06-05 | MedImmune Limited | ANTIBODIES DIRECTED TO alphaVbeta6 AND USES THEREOF |
| US9512236B2 (en) | 2006-12-19 | 2016-12-06 | Ablynx N.V. | Amino acid sequences directed against GPCRS and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders |
| DK2141997T3 (da) | 2007-03-30 | 2013-02-11 | Sloan Kettering Inst Cancer | Konstitutiv ekspression af co-stimulatoriske ligander på adoptivt overførte t-lymfocytter |
| EP2192922A4 (en) | 2007-09-17 | 2010-09-29 | Univ California | INTERNATIONALIZING HUMAN MONOCLONAL ANTIBODIES TO PROMOTE IN SITU ON PROSTATAZELLES |
| WO2009051633A1 (en) | 2007-10-15 | 2009-04-23 | The Board Of Trustees Of The Leland Stanford Junior University | Gpcr crystalization method using an antibody |
| MX2010004482A (es) * | 2007-10-25 | 2010-07-06 | Trellis Bioscience Inc | Anticuerpos anti-proteina g vsr. |
| EP2242773B1 (en) | 2008-02-11 | 2017-06-14 | Cure Tech Ltd. | Monoclonal antibodies for tumor treatment |
| US9217032B2 (en) | 2010-01-08 | 2015-12-22 | Les Laboratoires Servier | Methods for treating colorectal cancer |
| EP2596017B1 (en) | 2010-07-22 | 2019-04-03 | John W. Schrader | Cross-protective antibody against influenza viral infection |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| WO2013033626A2 (en) * | 2011-08-31 | 2013-03-07 | Trustees Of Dartmouth College | Nkp30 receptor targeted therapeutics |
| CN103483452B (zh) | 2012-06-12 | 2021-08-13 | 上海细胞治疗集团有限公司 | 双信号独立的嵌合抗原受体及其用途 |
| WO2014087010A1 (en) | 2012-12-07 | 2014-06-12 | Ablynx N.V. | IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE |
| JO3519B1 (ar) | 2013-01-25 | 2020-07-05 | Amgen Inc | تركيبات أجسام مضادة لأجل cdh19 و cd3 |
| PT3613439T (pt) * | 2013-02-15 | 2021-05-12 | Univ California | Recetor de antigénio quimérico e métodos de utilização do mesmo |
| ES3058841T3 (en) * | 2013-03-15 | 2026-03-13 | Novartis Ag | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| US9890393B2 (en) | 2013-05-29 | 2018-02-13 | Cellectis | Methods for engineering T cells for immunotherapy by using RNA-guided CAS nuclease system |
| JP2017513818A (ja) | 2014-03-15 | 2017-06-01 | ノバルティス アーゲー | キメラ抗原受容体を使用する癌の処置 |
| MX2016017393A (es) | 2014-07-01 | 2017-09-05 | Pfizer | Diacuerpos heterodimericos biespecificos y sus usos. |
| EP3193915A1 (en) | 2014-07-21 | 2017-07-26 | Novartis AG | Combinations of low, immune enhancing. doses of mtor inhibitors and cars |
| PT3227339T (pt) | 2014-12-05 | 2022-01-14 | Eureka Therapeutics Inc | Recetores de antigénio quiméricos que têm como alvo o recetor 4 acoplado a proteína g e utilizações dos mesmos |
| KR20230159637A (ko) * | 2014-12-05 | 2023-11-21 | 메모리얼 슬로안 케터링 캔서 센터 | G-단백질 커플화 수용체를 표적화하는 항체 및 이의 사용 방법 |
| WO2017070608A1 (en) | 2015-10-23 | 2017-04-27 | Eureka Therapeutics, Inc. | Antibody/t-cell receptor chimeric constructs and uses thereof |
| BR112018011336A2 (pt) | 2015-12-04 | 2018-12-04 | Memorial Sloan-Kettering Cancer Center | anticorpo anti-fcrl5 isolado ou um fragmento de ligação ao antígeno do mesmo, anticorpo scfv anti-fcrl5 isolado, anticorpo isolado ou porção de ligação ao antígeno do mesmo, composição, imunoconjugado, molécula biespecífica, ácido nucleico isolado, vetor de expressão, célula hospedeira, método para detectar fcrl5 em uma célula ou tecido inteiro, método para tratar câncer em um indivíduo, uso do anticorpo ou fragmento de ligação ao antígeno do mesmo, kit para tratar câncer |
| JP7208010B2 (ja) | 2016-03-29 | 2023-01-18 | ユニバーシティ オブ サザン カリフォルニア | 癌を標的とするキメラ抗原受容体 |
| CA3018253A1 (en) | 2016-03-31 | 2017-10-05 | University Of Southern California | A highly sensitive and specific luciferase based reporter assay for antigen detection |
| CN108239144B (zh) | 2018-01-26 | 2021-05-25 | 重庆精准生物技术有限公司 | 改造的铰链及其在构建car骨架中的应用 |
| CA3116413A1 (en) | 2018-11-01 | 2020-05-07 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for g protein-coupled receptor class c group 5 member d (gprc5d) |
-
2015
- 2015-12-04 PT PT158656330T patent/PT3227339T/pt unknown
- 2015-12-04 CA CA2969864A patent/CA2969864A1/en active Pending
- 2015-12-04 SI SI201531772T patent/SI3227339T1/sl unknown
- 2015-12-04 MX MX2017007242A patent/MX385156B/es unknown
- 2015-12-04 IL IL252621A patent/IL252621B2/en unknown
- 2015-12-04 CN CN201580075557.4A patent/CN107428829B/zh active Active
- 2015-12-04 LT LTEPPCT/US2015/064102T patent/LT3227339T/lt unknown
- 2015-12-04 DK DK15865633.0T patent/DK3227339T3/da active
- 2015-12-04 AU AU2015357518A patent/AU2015357518B2/en active Active
- 2015-12-04 IL IL310130A patent/IL310130A/en unknown
- 2015-12-04 CN CN202111126092.4A patent/CN113683711A/zh active Pending
- 2015-12-04 KR KR1020177018389A patent/KR102612367B1/ko active Active
- 2015-12-04 WO PCT/US2015/064102 patent/WO2016090312A1/en not_active Ceased
- 2015-12-04 SG SG11201704547RA patent/SG11201704547RA/en unknown
- 2015-12-04 ES ES15865633T patent/ES2899779T3/es active Active
- 2015-12-04 RU RU2017123551A patent/RU2762359C2/ru active
- 2015-12-04 EP EP15865633.0A patent/EP3227339B1/en active Active
- 2015-12-04 CN CN202111119531.9A patent/CN113968912B/zh active Active
- 2015-12-04 JP JP2017529741A patent/JP6919091B2/ja active Active
- 2015-12-04 CN CN202410434671.2A patent/CN118271463A/zh active Pending
- 2015-12-04 EP EP21201788.3A patent/EP4015534A1/en active Pending
- 2015-12-04 MY MYPI2017000855A patent/MY192065A/en unknown
- 2015-12-04 HR HRP20211978TT patent/HRP20211978T1/hr unknown
- 2015-12-04 PL PL15865633T patent/PL3227339T3/pl unknown
- 2015-12-04 HU HUE15865633A patent/HUE057777T2/hu unknown
- 2015-12-04 RS RS20211596A patent/RS62870B1/sr unknown
- 2015-12-04 SG SG10202007326QA patent/SG10202007326QA/en unknown
- 2015-12-04 SM SM20220040T patent/SMT202200040T1/it unknown
-
2017
- 2017-06-05 SA SA517381665A patent/SA517381665B1/ar unknown
- 2017-06-05 US US15/613,800 patent/US10633426B2/en active Active
- 2017-06-05 MX MX2021008798A patent/MX2021008798A/es unknown
- 2017-06-05 PH PH12017501044A patent/PH12017501044A1/en unknown
-
2020
- 2020-02-21 US US16/798,151 patent/US10906956B2/en active Active
- 2020-02-21 US US16/798,059 patent/US11820806B2/en active Active
- 2020-02-21 US US16/798,104 patent/US11866478B2/en active Active
- 2020-11-30 JP JP2020198690A patent/JP2021040652A/ja not_active Withdrawn
-
2022
- 2022-01-06 AU AU2022200052A patent/AU2022200052A1/en not_active Abandoned
- 2022-02-07 CY CY20221100105T patent/CY1125008T1/el unknown
-
2023
- 2023-05-12 JP JP2023079310A patent/JP2023091037A/ja not_active Withdrawn
- 2023-11-22 US US18/517,766 patent/US20240294599A1/en active Pending
-
2025
- 2025-09-19 JP JP2025156538A patent/JP2025181929A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017537629A5 (enExample) | ||
| JP2017537925A5 (enExample) | ||
| RU2017123551A (ru) | Химерные антигенные рецепторы, нацеленные на рецептор, связанный с g-белками, и их применение | |
| RU2017123548A (ru) | Химерные антигенные рецепторы, нацеленные на антиген созревания в-клеток, и их применение | |
| JP2018504094A5 (enExample) | ||
| JP7267921B2 (ja) | プログラム細胞死（ｐｄ－１）に対するシングルドメイン抗体 | |
| US12421292B2 (en) | Anti-DLL3 chimeric antigen receptors and uses thereof | |
| US11951172B2 (en) | Therapeutic molecules that bind to LAG3 and PD1 | |
| AU2018363291A1 (en) | Single domain antibodies that bind to CD137 | |
| JP2021519072A (ja) | ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法 | |
| WO2016090337A1 (en) | Chimeric antigen receptors targeting fc receptor-like 5 and uses thereof | |
| HRP20241057T1 (hr) | Kimerni antigenski receptori na osnovu jedno-domenskih antitijela i načini njihove uporabe | |
| JP2016520074A5 (enExample) | ||
| EP3969474A1 (en) | Binding molecules | |
| JPWO2021016585A5 (enExample) | ||
| JPWO2020081988A5 (enExample) | ||
| RU2020123705A (ru) | Композиции vcar и способы применения | |
| RU2022123916A (ru) | Клетки, экспрессирующие химерные активирующие рецепторы и химерные стимулирующие рецепторы, и их применение | |
| NZ732574B2 (en) | Chimeric antigen receptors targeting g-protein coupled receptor and uses thereof | |
| NZ791176B2 (en) | Chimeric antigen receptors targeting bcma and methods of use thereof | |
| HK40001773A (en) | Chimeric antigen receptors targeting fc receptor-like 5 and uses thereof |